Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucagon, Other, Topics Aug 27 | 2025Novo Adds Additional Partners to NovoCare; American Regent Announces Gvoke VialDx Launch Purchase Blast
$599
Posted in: GLP-1RA, Topics Aug 26 | 2025Lilly’s Ph3 ATTAIN-2 Results Set the Stage for Obesity Global Regulatory Filings Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 25 | 2025MannKind Acquires scPharmaceuticals; Amgen Olpasiran Primary Prevention Study; Repatha Label Expansion; Signos Launches OTC Weight Loss Platform with Dexcom’s Stelo; Roche Initiates New Ph1 Muscle Composition Study Purchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Aug 21 | 2025Gubra Q2 ‘25 Earnings; Advances New Obesity AssetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 21 | 2025Obesity Spotlight: Is Amgen's QM MariTide Dosing Enough?Purchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i, Topics Aug 20 | 2025Novo’s Hiring Freeze; UK Advocates for SGLT2is for Treatment of T2DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 20 | 2025Viking’s Topline AE Data Scares the Street; Medtronic Q2 ‘25 Earnings; Novo Partners for Oral Peptide Research; Rezdiffra Gains EU Marketing Authorization; UK Approves Tzield; Luna Closes Series A Funding Round; Health Canada Approves FLOW; EMA Accepts NewAmsterdam’s Obicetrapib MAA Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 18 | 2025Wegovy MASH Label Analysis; Ozempic Offered Through NovoCarePurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Aug 15 | 2025Lilly Addresses Global Drug Cost Changes; BioAge Ph1 NLRP3i Trial UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 14 | 2025Zealand Q2 ‘25 Earnings; Lilly Raises Mounjaro Prices in UK; Lilly Partners with Superluminal for Obesity Drug Discovery Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Aug 13 | 2025Ascletis Preclinical Obesity Data; Sagimet Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Autologous, Dual/triple agonist, Other, Topics Aug 12 | 2025UK Partners with Lilly for Obesity Program; Altimmune and Veru Q2 ‘25 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Aug 11 | 2025Medtronic Discloses its Abbott-Partnered CGM; Viking Registers Ph3 VK2735 Program; Roche Initiates H2H CT-996 vs Rybelsus in T2DM; Veru Shares New Formulation for EnobosarmPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 08 | 2025Tandem, Skye, Arrowhead, Gilead, Xeris, Viatris, Biocon, and 89bio Q2 ‘25 Earnings; Novo’s US Marketing Head Steps Down Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Aug 07 | 2025Novo London, Insulet, Senseonics, and MetaVia Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Aug 07 | 2025Lilly Leaves Door Open for Novo; Lilly Q2 ‘25 EarningsPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 07 | 2025Amgen and MannKind Q2 ’25 Earnings; Sava Raises $19M for Biosensor Development; MetaVia Extends Ph1 Obesity Study Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Aug 07 | 2025Novo Cleans Out Pipeline; Q2 ‘25 Earnings Update Purchase Blast
$599
Posted in: Autologous, Dual/triple agonist, GLP-1RA, Other, Topics Aug 06 | 2025Novo Sues Compounders…Again; Pfizer, Madrigal, Vertex, Corbus, and Esperion Q2 ‘25 Earnings; Innovent Receives IND clearance for Oral GLP-1RA; Vivani Data for Semaglutide Implant Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 04 | 2025Noom to Sell “Microdoses” of Wegovy; Sanofi Initiates Ph3 Tzield Study; MetaVia Partners for TA Discovery; Ypsomed Completes Sale of Diabetes Care Business Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
